Torrent Pharmaceuticals Ltd is a dynamic pharma company with a strong focus on branded generics, R&D-led innovation, and international expansion. Its consistent financial performance and commitment to healthcare make it a key player in the Indian and global pharmaceutical industry.

---

Torrent Pharmaceuticals Ltd – Company Overview

---

Basic Information

Attribute	Details
Company Name	Torrent Pharmaceuticals Ltd
Founded	1959 (as Trinity Laboratories)
Headquarters	Ahmedabad, Gujarat, India
Corporate Office	Torrent House, Off Ashram Road, Ahmedabad – 380009
Chairman	Sudhir Mehta
Managing Director & CEO	Jinesh Shah (current, 2025 update)
Parent Group	Torrent Group
Stock Exchange Listings	NSE: TORNTPHARMBSE: 500420
ISIN Code	INE685A01028
Industry	Pharmaceuticals
Website	www.torrentpharma.com

---

Business Profile

Torrent Pharmaceuticals Ltd is one of India’s leading pharmaceutical companies, part of the ₹25,000+ crore Torrent Group. The company specializes in:

• Therapeutic Areas: Cardiovascular (CV), Central Nervous System (CNS), Gastrointestinal, Diabetology, Anti-infectives, Pain Management, Oncology, Nephrology.
• Business Segments: Branded generics, specialty, OTC products, and APIs.
• Presence: Operates in 40+ countries with strongholds in India, Brazil, Germany, US, and other key global markets.

---

Global Presence

Region	Presence
India	Headquarters and major revenue base
United States	Strong presence in generics
Brazil	Among top 10 pharma companies
Germany	Robust operations post-Heumann acquisition
Rest of World	40+ countries in Latin America, Europe, and Asia

---

Research & Development

Attribute	Details
R&D Centers	4 R&D centers globally (India & overseas)
R&D Spend (FY 2024)	₹875+ crore (approx. 9% of revenue)
Pipeline	200+ ANDAs filed, 100+ DMFs filed in US and EU
Focus	NDDS, niche technologies, complex generics

---

Manufacturing Facilities

Torrent Pharma has 7 state-of-the-art manufacturing facilities, including:

• Indrad (Gujarat)
• Dahej (Gujarat)
• Sikkim
• Pithampur (Madhya Pradesh)
• Baddi (Himachal Pradesh)
• Visakhapatnam (API plant)
• Belewada, Andhra Pradesh (new investment in pipeline)

Certifications: USFDA, WHO-GMP, TGA, MHRA, ANVISA, EMA.

---

Financial Highlights (FY 2024–25)

Financial Metric	Value (approx.)
Revenue	₹10,850 crore
Net Profit	₹1,830 crore
EBITDA Margin	~26%
Market Capitalization	₹70,000+ crore (as of June 2025)
R&D Investment	₹875 crore

Note: Financials based on latest publicly available data & projections.

---

Recent Developments (2024–2025)

• Acquired dermatology portfolio from Curatio (India)
• Expanded oncology research pipeline
• Green energy adoption in Dahej & Indrad plants
• Launched 20+ products in US generics market
• Improved India market rank to top 10 branded pharma players

---

Leadership Team

Name	Designation
Sudhir Mehta	Chairman
Jinesh Shah	Managing Director & CEO
Sanjay Gupta	Director (Finance)
Bhavin Mehta	Director (International Ops)
Mehul Mehta	Director (Strategy & Planning)

---

Product Portfolio (Key Therapies)

• Cardiovascular – BP medications, cholesterol drugs
• CNS – Epilepsy, anxiety, schizophrenia
• Diabetology – Oral anti-diabetics, insulin combos
• Gastro – Antacids, PPIs
• Women’s Health – Hormonal therapies
• Oncology – Targeted therapies and injectables (emerging)
• Nephrology – Renal care products

---

CSR & Sustainability

• Torrent Foundation runs schools, hospitals, and skill development programs.
• Active in water conservation, rural electrification, and healthcare outreach.
• ESG Rating: High compliance with environmental and governance norms.

---

Contact Details

• Corporate Office: Torrent House, Off Ashram Road, Ahmedabad – 380009, Gujarat, India
• Phone: +91-79-26599000
• Email: info@torrentpharma.com
• Investor Queries: investorservices@torrentpharma.com

---

---